STOCK TITAN
  1. Home
  2. News
  3. SRTS

Sensus Healthcare Inc - SRTS STOCK NEWS

Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.

Sensus Healthcare, Inc. (Nasdaq: SRTS) is a leading medical device company dedicated to providing non-invasive and cost-effective treatments for non-melanoma skin cancer and keloids. Utilizing a proprietary low-energy x-ray radiation technology known as Superficial Radiation Therapy (SRT), Sensus Healthcare has made significant advancements in the field over more than a decade of dedicated research and development. The company’s flagship products, the SRT-100™ and SRT-100 Vision™, effectively and safely treat a variety of oncological and non-oncological skin conditions, including basal cell and squamous cell skin cancers, as well as keloids.

Based in Boca Raton, Florida, Sensus Healthcare focuses on creating innovative, minimally-invasive solutions that address critical medical needs. The company has recently announced a multi-faceted collaboration with CureRays, a radiation oncology specialist organization headquartered in Atlanta and Grass Valley, California. This partnership aims to enhance the reach and efficacy of Sensus's SRT technology, further solidifying its position as a leader in the non-invasive treatment market.

Sensus Healthcare generates the majority of its revenue from customers within the United States, offering products and services that meet the highest standards of safety and effectiveness. The company’s proprietary technology has been incorporated into its diverse portfolio, which includes the SRT-100™, SRT-100 Vision™, and a comprehensive Sentinel service program that ensures optimal device performance and customer satisfaction.

Investors and stakeholders are encouraged to stay informed about Sensus Healthcare’s latest developments. Recently, the company announced it would hold a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024 and provide updates on recent and upcoming milestones. This call will offer an in-depth overview of the company’s financial health and strategic initiatives.

For more detailed information about Sensus Healthcare, its innovative technology, products, and recent news, please visit Sensus Healthcare’s official website.

News

Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities

Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) has been issued a new patent by the USPTO for a radiotherapy mobile and wireless device workflow management system. The patent covers systems and methods for treating patients with a radiotherapy system combining high-frequency ultrasound and optical imaging data. This technology is a treatment-planning system that fuses a radiation therapy device with a high-frequency ultrasound (the SRT-100 Vision) to guide clinicians in creating treatment plans. The patent also covers scheduling patient appointments, detecting medical equipment status, and communicating information on status to a service engineer. This new patent adds to Sensus Healthcare's valuable intellectual property portfolio and ensures protection for their innovative products for years to come.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
none
-
News

Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements

Rhea-AI Summary
Sensus Healthcare, Inc. announces a collaboration with CureRays, a radiation oncology specialist organization, to research new indications for Sensus' superficial radiotherapy (SRT and IG-SRT) to include inflammatory diseases. CureRays will also provide oversight and supervision for Sensus' dermatology customers to ensure patient safety and regulatory compliance. The collaboration aims to broaden the market for Sensus' products, starting with arthritis. CureRays is led by Dr. Mohammad K. Khan and Dr. Clayton Hess, who are focused on radiation treatments for patients, radiation consulting for physicians, and the conduct of clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.72%
Tags
none
-
News

Sensus Healthcare Announces Retirement of Director Samuel O’Rear

Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) announces the retirement of Samuel O'Rear from the Board of Directors and the appointment of Michael J. Sardano as a Director. The company expresses gratitude to O'Rear for his dedicated service and welcomes Sardano, highlighting his contributions to the company's milestones. O'Rear reflects on his 50 years of professional experiences in the healthcare industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
News

Sensus Healthcare to Host Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Thursday, February 8, 2024

Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on February 8, 2024, to discuss the financial results for the fourth quarter and full year 2023, along with a business update and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
conferences earnings
-
News

Sensus Healthcare Announces Preliminary 2023 Revenue Exceeds $23 Million

Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) announces preliminary unaudited financial results for the three and 12 months ended December 31, 2023. The company expects to report revenue for the fourth quarter of 2023 of more than $12 million, with full-year revenue expected to exceed $23 million. They also achieved their guidance to ship more than 60 SRT systems during 2023. The company experienced a strong uptick in business during the fourth quarter despite customer impact from inflation and interest rates in the first three quarters of 2023. Sensus Healthcare plans to announce full financial results and hold an investment community conference call on February 8, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.32%
Tags
none
-
News

Sensus Healthcare Reports Third Quarter 2023 Financial Results

Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) announces financial results for the three and nine months ended September 30, 2023, reflecting lower revenues due to seasonality and macroeconomic conditions. The company reported revenues of $3.9 million, net loss of $1.5 million, and $20.5 million in cash and cash equivalents. The financial results were impacted by lower superficial radiotherapy (SRT) unit sales and lower sales to a large customer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.41%
Tags
earnings
News

Sensus Healthcare to Host Third Quarter 2023 Financial Results and Business Update Conference Call on Thursday, November 9, 2023

Rhea-AI Summary
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on November 9, 2023, at 4:30 p.m. Eastern time to discuss the financial results for Q3 2023. The call will include a business update and discussion on recent and upcoming milestones. Participants can pre-register for the call to receive a unique dial-in number. The call will be webcast live and a telephone replay will be available until December 9th.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
conferences earnings
-
News

Sensus Healthcare to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference

Rhea-AI Summary
Sensus Healthcare to present at Roth MKM 2023 Healthcare Opportunities Conference and participate in Fall Clinical Dermatology Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News

Sensus Healthcare Sells Superficial Radiotherapy System to Cape Cod Hospital

Rhea-AI Summary
Sensus Healthcare announces the shipment of an SRT-100+ System to Cape Cod Hospital, marking their ongoing success in the U.S. Northeast region. More hospitals are inquiring about SRT as a non-invasive skin cancer treatment option. Sensus will be demonstrating its products at the ASTRO Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none
News

Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego

Rhea-AI Summary
Sensus Healthcare to showcase its SRT devices at ASTRO Annual Meeting, presenting advancements in superficial radiotherapy for non-melanoma skin cancer and keloids. The devices offer a non-surgical, painless, and cosmetically appealing treatment option. Sensus Healthcare aims to enhance patient care within radiation oncology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
none

FAQ

What is the current stock price of Sensus Healthcare (SRTS)?

The current stock price of Sensus Healthcare (SRTS) is $5.38 as of February 21, 2025.

What is the market cap of Sensus Healthcare (SRTS)?

The market cap of Sensus Healthcare (SRTS) is approximately 91.7M.

What is Sensus Healthcare, Inc.?

Sensus Healthcare, Inc. is a medical device company specializing in non-invasive treatments for non-melanoma skin cancer and keloids, utilizing proprietary Superficial Radiation Therapy (SRT) technology.

What products does Sensus Healthcare offer?

Sensus Healthcare offers the SRT-100™ and SRT-100 Vision™, which are devices designed to treat oncological and non-oncological skin conditions.

What is Superficial Radiation Therapy (SRT)?

Superficial Radiation Therapy (SRT) is a low-energy x-ray radiation technology used by Sensus Healthcare to treat conditions like non-melanoma skin cancer and keloids effectively and safely.

Where is Sensus Healthcare based?

Sensus Healthcare is based in Boca Raton, Florida.

What recent collaborations has Sensus Healthcare announced?

Sensus Healthcare recently announced a collaboration with CureRays, a radiation oncology specialist organization based in Atlanta and Grass Valley, California.

How does Sensus Healthcare generate its revenue?

Sensus Healthcare generates the majority of its revenue from customers in the United States through the sale of its medical devices and services.

What is the Sentinel service program?

The Sentinel service program is a comprehensive service offered by Sensus Healthcare to ensure optimal device performance and customer satisfaction.

When is the next conference call for Sensus Healthcare?

Sensus Healthcare will hold a conference call on May 9, 2024, to discuss the financial results for the first quarter of 2024 and provide updates on recent and upcoming milestones.

Where can I find more information about Sensus Healthcare?

More information about Sensus Healthcare can be found on their official website at www.sensushealthcare.com.

What conditions can Sensus Healthcare’s devices treat?

Sensus Healthcare’s devices can treat oncological skin conditions like basal cell and squamous cell skin cancers, as well as non-oncological conditions such as keloids.
Stock SRTS logo
Sensus Healthcare Inc

Nasdaq:SRTS

SRTS Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

SRTS Stock Data

91.71M
13.57M
19.01%
24.27%
3.27%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
BOCA RATON